Earnings

AngioDynamics Affirms FY2027 Adj EPS Guidance of $(0.29)-$(0.24) vs $(0.27) Est; Affirms FY2027 Sales Guidance of $336.000M-$341.000M vs $337.400M Est

Oct 8, 2026 · 06:03 AM ET· updated 48m ago

AngioDynamics (NASDAQ:ANGO) affirms FY2027 Adj EPS guidance from $(0.29)-$(0.24) to $(0.29)-$(0.24) vs $(0.27) analyst estimate. Affirms FY2027 sales outlook from $336.000 million-$341.000 million to $336.000

Why It Matters

AngioDynamics kept its forecasts the same for next year. The company expects to lose money per share and make around $338 million in sales, which is close to what experts predicted.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ANGO14.30

+0.11 (+0.78%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.